Sentry BioPharma Services ApS: Financial statements 2022
CVR: 41330619
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Sentry BioPharma Services ApS (CVR 41330619) has filed annual accounts for 2022. In 2022, the company reported a net result of DKK -2,818,910 compared with DKK -1,055,832 the year before. Equity in the 2022 report amounted to DKK -4,197,014.
- Profit/Loss
- DKK -2,818,910
- Equity
- DKK -4,197,014
- Total Assets
- DKK 2,697,453
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | - | -2.8 mio. | -4.2 mio. | - |
| 2021 | - | - | -1.1 mio. | -1.4 mio. | - |
Official annual report
Keep an eye on Sentry BioPharma Services ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of November 9, 2022, Ole Meier Sørensen is registered as director of Sentry BioPharma Services ApS.
Sentry BioPharma Services ApS has published its annual report for 2021. The net result was DKK -1,055,832.
About Sentry BioPharma Services ApS
Sentry BioPharma Services ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2020. The company is registered under the industry Oplagring og opbevaring. The management consists of Timothy Jon Mitchell and William Maxwell Tuttle. The company is owned by Sentry BioPharma Services, Inc.. The company has 1 employee (2026). In 2025, the company reported a net result of DKK -537,511 compared with DKK -3,275,518 the year before. Equity in the 2025 report amounted to DKK -11,627,396.